Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CING, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| CTx-1301 - Dexmethylphenidate 12.5mg | ADHD | Phase 3 · NCT05924594 | Suspended |
| CTx-1301-Dexmethylphenidate 12.5 mg (tit | ADHD | Phase 3 · NCT05286762 | Completed |
| Dexmethylphenidate | ADHD | Phase 1/2 · NCT04138498 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CING holds $28.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.4M/quarter from operations, an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 78 · High
These uncertainties raise substantial doubt about our ability to continue as a going concern for one year after the issuance date of our financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CING files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Falcon Creek Capital Advisor LLC | 5%+ holder (13D) | 3,856,766 | 26.52% | 2026-03-24 |
| Vanguard Capital Management LLC | Institution (13F) | 570,873 | 3.93% | 2026-06-30 |
| Chicago Partners Investment Group LLC | Institution (13F) | 188,429 | 1.30% | 2026-06-30 |
| Raymond James Financial, Inc. | Institution (13F) | 166,898 | 1.15% | 2026-06-30 |
| Kestra Advisory Services, LLC | Institution (13F) | 151,500 | 1.04% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 144,636 | 0.99% | 2026-06-30 |
| Renaissance Technologies, LLC | Institution (13F) | 127,500 | 0.88% | 2026-06-30 |
| Peter J. Werth Director · +67,490 options |
Insider | 117,541 | 0.81% | 2026-02-06 |
| Thomas Jeffrey Hargroves Director · +112,821 options |
Insider | 97,468 | 0.67% | 2026-02-13 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 79,160 | 0.54% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 53,130 | 0.37% | 2026-06-30 |
| Bcv Asset Management Inc. | Institution (13F) | 51,200 | 0.35% | 2026-06-30 |
Share count 14,541,826 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-16 filed 2026-07-20 |
Schaffer Shane J. |
Option award (A) | 197,650 | – | – |
| 2026-07-16 filed 2026-07-20 |
Schaffer Shane J. |
Option award (A) | 97,350 | – | – |
| 2026-07-16 filed 2026-07-20 |
Silva Raul R. |
Option award (A) | 53,600 | – | – |
| 2026-07-16 filed 2026-07-20 |
Silva Raul R. |
Option award (A) | 26,400 | – | – |
| 2026-07-16 filed 2026-07-20 |
Werth Peter J. |
Option award (A) | 20,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CING and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →